| 1/9/2017 | CV | Market Commentary: Ariad Pharmaceuticals jumps on Takeda takeover news; AMAG paper suffers; Nabors deal on tap
|
| 1/9/2017 | CV | Market Commentary: Morning Commentary: Ariad Pharmaceuticals jumps on Takeda takeover news; Dow Jones in focus
|
| 9/20/2016 | CV | Market Commentary: Convertibles quiet ahead of central bank news; Intel bond ‘flat to slightly up’; Ariad eyed
|
| 9/20/2016 | CV | Market Commentary: Morning Commentary: Convertibles quiet ahead of central bank news; Ariad Pharmaceuticals in focus
|
| 5/31/2016 | PP | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
| 5/31/2016 | CV | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
| 5/31/2016 | CV | Market Commentary: Morning Commentary: Health care in focus as sector lifts following Celator acquisition news
|
| 2/5/2016 | CV | Market Commentary: Hess mandatory trades around par; LinkedIn falls but not as badly as shares; Workday drops
|
| 9/18/2015 | PP | Market Commentary: Convertibles quiet, steady post Fed; some health-care names better bid; Medicines edges up
|
| 9/18/2015 | CV | Market Commentary: Convertibles quiet, steady post Fed; some health-care names better bid; Medicines edges up
|
| 9/2/2015 | PP | Market Commentary: Ariad tumbles outright on nixed takeout talks; HeartWare shares plunge; Verint up a little
|
| 9/2/2015 | CV | Market Commentary: Ariad tumbles outright on nixed takeout talks; HeartWare shares plunge; Verint up a little
|
| 9/2/2015 | CV | Market Commentary: Morning Commentary: Ariad in focus as takeout talks dropped; Whiting Petroleum better; Verint up
|
| 8/28/2015 | CV | Market Commentary: Convertibles steady to end turbulent week; Intel up in line with shares; energy names up
|
| 7/29/2015 | PV | Ariad gets $100 million synthetic-royalty financing from PDL BioPharma
|
| 6/13/2014 | CV | Market Commentary: Verint flat to richer dollar neutral; Exelon flat dollar neutral since issue; Finisar off
|
| 6/12/2014 | PP | Market Commentary: Exelon makes strong debut; upsized j2 Global, Ariad tread water after early weakness
|
| 6/12/2014 | CV | Market Commentary: Exelon makes strong debut; upsized j2 Global, Ariad tread water after early weakness
|
| 6/12/2014 | CV | Market Commentary: Morning Commentary: New Exelon equity units edge up on debut; other new paper weaker
|
| 6/12/2014 | CV | New Issue: Ariad prices upsized $200 million five-year convertibles to yield 3.625%, up 32.5%
|
| 6/11/2014 | CV | Market Commentary: Penn Virginia gains; planned Exelon adds in gray market; secondary valuations ‘come in’
|
| 6/11/2014 | CV | Ariad to price $175 million five-year convertibles to yield 3.25%-3.75%, up 30%-35%
|
| 7/24/2013 | SP | JPMorgan to price 8%-10.2% airbag yield optimization notes on Ariad
|
| 12/28/2012 | SP | New Issue: RBC prices $753,000 airbag yield optimization notes linked to Ariad Pharmaceuticals
|
| 12/19/2012 | SP | RBC plans 9%-11% airbag yield optimization notes on Ariad Pharma
|
| 12/14/2011 | CVHYPF | Ariad files automatic shelf registration for debt, stock, preferreds
|
| 1/11/2010 | CVHY | Ariad Pharmaceuticals files $125 million stock, preferreds, debt shelf
|
| 2/20/2009 | PP | New Issue: Ariad aims for $24.3 million in direct offering of shares
|
| 2/20/2009 | PP | Market Commentary: Cadence wraps $85.54 million stock placement; Beacon Power to raise $18 million through stock sale
|
| 1/30/2007 | CV | Aria Pharmaceuticals files $100 million debt, stock shelf
|
| 11/13/2006 | BT | Ariad says finding ex-U.S. partner for AP23573 is top priority
|
| 11/13/2006 | BT | Market Commentary: Solexa up 20.5%, Illumina down 12% on stock merger; Nabi slips; Favrille falls 22%; Ariad steady
|
| 11/2/2006 | BT | Ariad ends quarter with $39.2 million of cash, net loss grows to $47.6 million
|
| 10/20/2006 | BT | Market Commentary: BioVex IPO pulled; Ariad dives; Encysive off; Vical spikes 10%; Amgen higher ahead of results
|
| 10/20/2006 | BT | New Issue: Ariad raises $14.5 million in follow-on of 3.1 million shares at $4.65 each, versus $5.18 close
|
| 10/19/2006 | BT | Ariad to sell to 3,112,945 shares in follow-on via Credit Suisse
|
| 10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
| 9/18/2006 | BT | Ariad planning to test AP23573 in wide range of earlier-stage sarcomas in phase 3 clinical trial
|
| 9/12/2006 | BT | Ariad: Court denies motion to dismiss Amgen patent lawsuit
|
| 9/7/2006 | BT | JMP drops Ariad at market outperform
|
| 9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
| 8/15/2006 | BT | Ariad gets patent covering mTOR inhibitors
|
| 8/8/2006 | BT | Ariad reports second-quarter net loss of $17 million
|
| 8/7/2006 | BT | Market Commentary: Encysive sinks on dilution worries; Acorda higher; Genitope gains; Ariad off
|
| 8/1/2006 | BT | Market Commentary: ViroPharma spikes ahead of 2Q; Genomic off on lower outlook; Genitope falls 12% on new data
|
| 6/5/2006 | BT | Ariad says AP23573 extended disease stability, was well tolerated in sarcoma trial
|
| 5/30/2006 | BT | JMP's Biotechnology Industry Overview
|
| 5/22/2006 | BT | Ariad to present new data on novel mTOR inhibitor for cancer at annual oncology meeting
|
| 5/9/2006 | BT | JMP reiterates Ariad at market outperform
|
| 5/9/2006 | BT | Market Commentary: Hollis-Eden loses in advance of first-quarter report; Tercica dives 22% after close; Curis rises 17%
|
| 5/9/2006 | BT | Ariad says Eli Lilly lawsuit revenues 'may be important,' will move AP23573 to phase 3 testing
|
| 5/4/2006 | BT | Ariad, co-plaintiffs awarded more than $65 million in Lilly NF-(kappa)B patent infringement lawsuit
|
| 4/24/2006 | BT | Ariad to defend patent infringement claims by Amgen, others
|
| 4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
| 4/3/2006 | BT | Ariad says preclinical oncology programs show anticancer activity
|
| 2/14/2006 | BT | Ariad begins clinical trial of oral AP23573 in cancer patients
|
| 2/9/2006 | BT | Ariad reiterated at market outperform by JMP
|
| 11/17/2005 | BT | Ariad announces oral dosage safe for anti-cancer drug AP23573
|
| 11/16/2005 | BT | Ariad's AP23573 produces tumor regression in 27% of sarcoma patients in phase 2 trial
|
| 11/15/2005 | BT | Ariad's AP23573 for sarcomas named orphan drug by European regulator
|
| 8/19/2005 | BT | Ariad greenshoe exercised, raising stock sale to $62.1 million
|
| 8/5/2005 | BT | Market Commentary: Advanced Life Sciences IPO gets off at big price cut; AtriCure IPO bounces; Coley's IPO ahead
|
| 8/5/2005 | BT | New Issue: Ariad raises $54 million in upsized follow-on at $7.20, discounted from $7.34 close
|
| 8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
| 8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|
| 8/1/2005 | BT | Ariad kept by JMP at market outperform
|
| 8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
| 8/1/2005 | BT | Ariad plans 6 million share follow-on; posts wider second-quarter net loss
|
| 7/18/2005 | BT | Ariad initiated by Global Crown at underweight
|
| 6/28/2005 | BT | Ariad initiated by Oppenheimer at buy
|
| 6/27/2005 | BT | Ariad initiated by Bear Stearns at outperform
|
